Farrell Simon

Insider Reports History

Location
New Haven, CT
Signature
/s/ Christopher Galletta, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Farrell Simon:

Company Role Class Num Shares Value Price $ Report Date Ownership
Trevi Therapeutics, Inc. Chief Commercial Officer Common Stock 76,900 $549,820 $7.15 10 Mar 2025 Direct
Trevi Therapeutics, Inc. Chief Commercial Officer Stock Option (right to buy) 160,000 19 Feb 2026 Direct
Trevi Therapeutics, Inc. Chief Commercial Officer Performance Stock Option (right to buy) 110,400 31 May 2025 Direct

Insider Reports Filed by Farrell Simon

Symbol Company Period Transactions Value $ Form Type Role Filing Time
TRVI Trevi Therapeutics, Inc. 19 Feb 2026 1 $0 4 Chief Commercial Officer 20 Feb 2026, 16:15
TRVI Trevi Therapeutics, Inc. 31 May 2025 1 $0 4 Chief Commercial Officer 03 Jun 2025, 16:00
TRVI Trevi Therapeutics, Inc. 10 Mar 2025 9 -$227,225 4 Chief Commercial Officer 12 Mar 2025, 16:00
TRVI Trevi Therapeutics, Inc. 18 Feb 2025 1 $0 4 Chief Commercial Officer 20 Feb 2025, 16:00
TRVI Trevi Therapeutics, Inc. 15 Feb 2024 1 $0 4 Chief Commercial Officer 16 Feb 2024, 16:43
TRVI Trevi Therapeutics, Inc. 20 Jun 2023 2 +$3,194 4 Chief Commercial Officer 21 Jun 2023, 16:00
TRVI Trevi Therapeutics, Inc. 07 Mar 2023 2 +$9,581 4 Chief Commercial Officer 08 Mar 2023, 15:00
TRVI Trevi Therapeutics, Inc. 16 Feb 2023 1 $0 4 Chief Commercial Officer 16 Feb 2023, 16:30
TRVI Trevi Therapeutics, Inc. 16 Feb 2023 0 $0 3 Chief Commercial Officer 16 Feb 2023, 16:26